Detección y cuantificación del virus de la enfermedad de linfocistis mediante ensayo ICC-RT-PCR (integrated cell culture-RT-PCR)

La enfermedad de linfocistis es la enfermedad de etiología viral más frecuentemente detectada en la acuicultura marina europea, siendo la principal patología de origen vírico descrita en doradas cultivadas. El agente etiológico de esta enfermedad es el virus de la enfermedad de linfocistis (LCDV), miembro del género Lymphocystivirus, perteneciente a la familia Iridoviridae. Se han desarrollado diversos protocolos de PCR y PCR a tiempo real que permiten la detección y cuantificación del LCDV en diversas muestras, si bien no aportan ninguna indicación de la infectividad de los virus detectados. La detección de partículas víricas infectivas requiere la utilización de cultivos celulares, pero en el caso del LCDV la observación de efectos citopáticos (CPE) es difícil y a menudo está sujeta a subjetividad, especialmente en muestras con baja carga vírica. Por este motivo, en el presente trabajo se ha desarrollado un ensayo de ICC-RT-PCR (Integrated Cell Culture-RT-PCR) que permite la detección de partículas infectivas del LCDV. Este ensayo se ha aplicado en combinación con el método del número más probable (NMP) para la determinación del título infectivo en cultivos celulares. El protocolo de ICC-RT-PCR desarrollado permitió la detección de mRNA viral a partir de células SAF-1 inoculadas con un título infectivo de LCDV de 0,1 TCID50/ml, procesadas a los 5 d p.i, mientras que el límite de detección mediante observación de CPE fue de 10 TCID50/ml a 14 d p.i. La sensibilidad de la técnica he permitido la detección de partículas infectivas del LCDV en ejemplares de dorada asintomáticos, donde no se observaron CPE en cultivos celulares inoculados en paralelo y mantenidos hasta 14 d p.i. Este protocolo también se ha aplicado para la determinación del título infectivo de diferentes aislados víricos obtenidos a partir de peces enfermos, reduciéndose de forma considerable el tiempo necesario para realizar la titulación en comparación con el método de la dosis infectiva 50% en cultivos celulares (TCID50) (5 d versus 14-21 d, respectivamente). Así mismo, se han titulado stocks víricos obtenidos en cultivos celulares, donde la carga vírica es inferior al límite de detección del ensayo de observación de CPE. En conclusión, el protocolo de ICC-RT-PCR desarrollado es una técnica sensible, rápida y útil para la detección y cuantificación de LCDV infectivos, lo que la convierte en una herramienta adecuada para el estudio de esta patología viral.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tec

Determinación de órganos diana para la multiplicación y persistencia del virus de la enfermedad de linfocistis (LCDV) en dorada (Sparus aurata, L.)

La enfermedad de linfocistis es la única patología de etiología viral descrita en dorada cultivada En la cuenca mediterr nea, la prevalencia es cercana al 100 , ocasionando graves p rdidas económicas debido a la imposibilidad de comercializar los peces afectados En el presente trabajo se ha abordado el estudio de la patog nesis del virus de la enfermedad de linfocistis (LCDV) en dorada, además se han establecido los órganos implicados en la multiplicación vírica Para ello, se ha diseñado un protocolo de hibridación in situ empleando sondas RNA marcadas con digoxigenina dirigidas contra el gen que codifica la proteína principal de la cápside (MCP) viral, y se ha evaluado en poblaciones de dorada. En paralelo, se ha procedido a la cuantificación del número de copias de genoma viral por PCR a tiempo real y cuantificación relativa de la transcripción del gen que codifica la MCP viral mediante qRT-PCR. Los resultados obtenidos indican que el LCDV establece una infección sistémica en alevines de dorada, pudiendo detectarse señal de hibridación tanto en órganos internos (hígado, bazo, riñón) como en músculo y aleta. También se han observado diversos daños histopatológicos en animales enfermos, mientras que en animales recuperados de la enfermedad estos daños parecen revertir, aunque en estos animales la infección persiste, si bien sólo a niveles detectables mediante PCR a tiempo real.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

CASA-Mot technology: how results are affected by the frame rate and counting chamber

For over 30 years, CASA-Mot technology has been used for kinematic analysis of sperm motility in different mammalian species, but insufficient attention has been paid to the technical limitations of commercial computer-aided sperm analysis (CASA) systems. Counting chamber type and frame rate are two of the most important aspects to be taken into account. Counting chambers can be disposable or reusable, with different depths. In human semen analysis, reusable chambers with a depth of 10 mm are the most frequently used, whereas for most farm animal species it is more common to use disposable chambers with a depth of 20 mm. The frame rate was previously limited by the hardware, although changes in the number of images collected could lead to significant variations in some kinematic parameters, mainly in curvilinear velocity (VCL). A frame rate of 60 frames s(-1) is widely considered to be the minimum necessary for satisfactory results. However, the frame rate is species specific and must be defined in each experimental condition. In conclusion, we show that the optimal combination of frame rate and counting chamber type and depth should be defined for each species and experimental condition in order to obtain reliable results

Impact of glucocorticoid on a cellular model of parkinson’s disease: Oxidative stress and mitochondrial function

Stress seems to contribute to the neuropathology of Parkinson’s disease (PD), possibly by dysregulation of the hypothalamic–pituitary–adrenal axis. Oxidative distress and mitochondrial dysfunction are key factors involved in the pathophysiology of PD and neuronal glucocorticoid-induced toxicity. Animal PD models have been generated to study the effects of hormonal stress, but no in vitro model has yet been developed. Our aim was to examine the impact of corticosterone (CORT) administration on a dopaminergic neuronal cell model of PD induced by the neurotoxin MPP+, as a new combined PD model based on the marker of endocrine response to stress, CORT, and oxidative-mitochondrial damage. We determined the impact of CORT, MPP+ and their co-incubation on reactive oxygen species production (O2−• ), oxidative stress cellular markers (advanced-oxidation protein products and total antioxidant status), mitochondrial function (mitochondrial membrane potential and mitochondrial oxygen consumption rate) and neurodegeneration (Fluoro-Jade staining). Accordingly, the administration of MPP+ or CORT individually led to cell damage compared to controls (p < 0.05), as determined by several methods, whereas their co-incubation produced strong cell damage (p < 0.05). The combined model described here could be appropriate for investigating neuropathological hallmarks and for evaluating potential new therapeutic tools for PD patients suffering mild to moderate emotional stress

Comments on ”A new conformal FDTD for lossy thin panels”

In the paper ”A new conformal FDTD for lossy thin panels” by M. R. Cabello et al., the appearance of spiky antiresonances in the simulation of the shielding properties of lossy thin-shell spherical cavities by FDTD, was categorised as spurious solutions. In this document, we briefly clarify this topic, and show that these solutions are not really spurious in the common interpretation of the term. Actually, they correspond to physical solutions, appearing due to lack of symmetry inherent to the staggered co-location nature of field components in FDTD

Ten years since the introduction of therapeutic hypothermia in neonates with perinatal hypoxic-ischaemic encephalopathy in Spain

More than a decade has passed since therapeutic hypothermia (TH) was introduced in Spain; this is the only neuroprotective intervention that has become standard practice in the treatment of perinatal hypoxic-ischaemic encephalopathy (HIE). This article aims to provide a current picture of the technique and to address the controversies surrounding its use. In the last 10 years, TH has been successfully implemented in the vast majority of tertiary hospitals in Spain, and more than 85% of newborns with moderate or severe HIE currently receive the treatment. The factors that can improve the efficacy of TH include early treatment onset (first 6 hours of life) and the control of comorbid factors associated with perinatal asphyxia. In patients with moderate HIE, treatment onset after 6 hours seems to have some neuroprotective efficacy. TH duration longer than 72 hours or deeper hypothermia do not offer greater neuroprotective efficacy, but instead increase the risk of adverse effects. Unclarified aspects are the sedation of patients during TH, the application of the treatment in infants with mild HIE, and its application in other scenarios. Prognostic information and time frame are one of the most challenging aspects. TH is universal in countries with sufficient economic resources, although certain unresolved controversies remain. While the treatment is widespread in Spain, there is a need for cooling devices for the transfer of these patients and their centralisationSe cumple ahora más de una década del inicio de la hipotermia terapéutica (HT) en España, la única intervención neuroprotectora que ha venido a ser práctica estándar en el tratamiento de la encefalopatía hipóxico-isquémica perinatal (EHI). El objetivo de este artículo es ofrecer un panorama actual y presentar las controversias surgidas alrededor de la aplicación de esta terapia. En esta década se ha implantado con éxito la HT en la gran mayoría de los hospitales terciarios de España y más del 85% de los recién nacidos con EHI moderada-grave reciben esta terapia. Entre los aspectos que pueden mejorar la eficacia de la HT están su inicio precoz dentro de las primeras 6 horas de vida y el control de factores comórbidos asociados a la asfixia perinatal. En los pacientes con EHI moderada el inicio después de las 6 horas parece mantener cierta eficacia neuroprotectora. Una duración de la HT mayor de 72 horas o un enfriamiento más profundo no ofrecen mayor eficacia neuroprotectora y aumentan el riesgo de efectos adversos. Persiste la controversia acerca de la sedación durante la HT, la aplicación de esta intervención a los neonatos con EHI leve y en otros escenarios. La información pronóstica y su marco temporal es uno de los aspectos más desafiantes. La HT es universal en países con recursos económicos, aunque existen puntos de controversia no resueltos. Si bien es un tratamiento generalizado en nuestro país, falta disponer de dispositivos para el traslado de estos pacientes y su centralizació

The importance of organizational variables in treatment time for patients with ST-elevation acute myocardial infarction improve delays in STEMI

Background: The time between arrival at the emergency department (ED) and balloon (D2B) in STEMI is one of the best indicators of the quality of care. Our aim is to describe treatment times and evaluate the causes of delay. Methods: This is an observational retrospective study, including all consecutive STEMI code patients ≥18 years old treated in the ED from 2013 to 2016.All the patients were stratified into two groups: delayed group with D2B > 70 min and non-delayed ≤70. The primary variable was D2B time. Findings: In total 327 patients were included, stratified according to their D2B as follows: 166 (67·48%) in the delayed group and 80 (32·52%) in the non-delayed group. The delayed group was older (p = 0·005), with more females (p = 0·060) and more atypical electrocardiogram (ECG) STEMI signs or symptoms (p = 0·058) (p = 0·087). Predictors of shorter D2B time were: typical STEMI ECG signs and short training sessions for nurses on identifying STEMI patients. Interpretation: There are delays particularly in specific groups with atypical clinical presentations. Short training sessions aimed at emergency nurses correlate with shorter delay. This suggests that continuing training for emergency nurses, along with organizational strategies, can contribute to increasing the quality of care. Clinical trial number: NCT0433338

Neuronal Metabolism and Neuroprotection: Neuroprotective Effect of Fingolimod on Menadione-Induced Mitochondrial Damage

Imbalance in the oxidative status in neurons, along with mitochondrial damage, are common characteristics in some neurodegenerative diseases. The maintenance in energy production is crucial to face and recover from oxidative damage, and the preservation of different sources of energy production is essential to preserve neuronal function. Fingolimod phosphate is a drug with neuroprotective and antioxidant actions, used in the treatment of multiple sclerosis. This work was performed in a model of oxidative damage on neuronal cell cultures exposed to menadione in the presence or absence of fingolimod phosphate. We studied the mitochondrial function, antioxidant enzymes, protein nitrosylation, and several pathways related with glucose metabolism and glycolytic and pentose phosphate in neuronal cells cultures. Our results showed that menadione produces a decrease in mitochondrial function, an imbalance in antioxidant enzymes, and an increase in nitrosylated proteins with a decrease in glycolysis and glucose-6-phosphate dehydrogenase. All these effects were counteracted when fingolimod phosphate was present in the incubation media. These effects were mediated, at least in part, by the interaction of this drug with its specific S1P receptors. These actions would make this drug a potential tool in the treatment of neurodegenerative processes, either to slow progression or alleviate symptoms

Insulin-like growth factor II prevents oxidative and neuronal damage in cellular and mice models of Parkinson's disease

Oxidative distress and mitochondrial dysfunction, are key factors involved in the pathophysiology of Parkinson's disease (PD). The pleiotropic hormone insulin-like growth factor II (IGF-II) has shown neuroprotective and antioxidant effects in some neurodegenerative diseases. In this work, we demonstrate the protective effect of IGF-II against the damage induced by 1-methyl-4-phenylpyridinium (MPP+) in neuronal dopaminergic cell cultures and a mouse model of progressive PD. In the neuronal model, IGF-II counteracts the oxidative distress produced by MPP + protecting dopaminergic neurons. Improved mitochondrial function, increased nuclear factor (erythroid-derived 2)-like2 (NRF2) nuclear translocation along with NRF2-dependent upregulation of antioxidative enzymes, and modulation of mammalian target of rapamycin (mTOR) signalling pathway were identified as mechanisms leading to neuroprotection and the survival of dopaminergic cells. The neuroprotective effect of IGF-II against MPP + -neurotoxicity on dopaminergic neurons depends on the specific IGF-II receptor (IGF-IIr). In the mouse model, IGF-II prevents behavioural dysfunction and dopaminergic nigrostriatal pathway degeneration and mitigates neuroinflammation induced by MPP+. Our work demonstrates that hampering oxidative stress and normalising mitochondrial function through the interaction of IGF-II with its specific IGF-IIr are neuroprotective in both neuronal and mouse models. Thus, the modulation of the IGF-II/IGF-IIr signalling pathway may be a useful therapeutic approach for the prevention and treatment of PD